BRD5631 is an autophagy enhancer through an mTOR-independent pathway. It affects several cellular disease phenotypes linked to autophagy, including cell survival, protein aggregation, and inflammatory cytokine production.

BRD5631 (10 μM, 48 hours) leads to increased levels of LC3-II in HeLa cells. BRD5631 stimulates the formation of new autophagosomes. BRD5631 suppressed IL-1β secretion in an autophagy-dependent manner. BRD5631 does not enhance autophagy by directly inhibiting mTOR or the mTOR signaling pathway.

2446154-91-0

C30H35N3O4

501.62

BRD5631

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years